Eurofins Scientific (ERF) AI Stock Analysis

• Market Cap: €10.86B
• Dividend Yield: 1.01%
• Average Volume (3M): 355.17K
• Price to Earnings (P/E): 28.0
• Beta (1Y): 1.08
• Revenue Growth: 6.70%
• EPS Growth: 32.29%
• Country: FR
• Employees: 62,696
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.13
• Shares Outstanding: 182,163,000
• 10 Day Avg. Volume: 457,872
• 30 Day Avg. Volume: 355,172
• PEG Ratio: 1.77
• Price to Book (P/B): 1.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €53.85
• Price Target Upside: -9.68% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 74 Outperform
• Price Target: €64.00 ▲(7.35%Upside)

Eurofins Scientific's strong financial performance and positive technical indicators are balanced by a relatively high valuation. The stock benefits from robust cash flow and positive market momentum, making it an attractive option despite valuation concerns.

Eurofins Scientific Business Overview & Revenue Model

Company Description

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

How the Company Makes Money

Eurofins Scientific generates revenue primarily through the provision of testing and laboratory services. Its key revenue streams include analytical testing services for food and feed, environmental testing, pharmaceutical testing, and clinical diagnostics. The company serves a broad range of industries, including agriculture, food and beverage, pharmaceuticals, biotechnology, and healthcare, which require regular testing to comply with regulatory standards and ensure product safety and quality. Eurofins' extensive network of laboratories and its investment in cutting-edge technology enable it to deliver high-quality services efficiently, which drives client retention and attracts new business. Strategic acquisitions and partnerships also play a significant role in expanding its service capabilities and geographical reach, further contributing to its revenue growth.

Eurofins Scientific Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
8.38B	6.95B	6.51B	6.71B	6.72B	5.44B
	Gross Profit
1.02B	4.71B	620.40M	4.49B	4.57B	3.69B
	EBIT
844.70M	0.00	546.80M	857.70M	1.26B	906.30M
	EBITDA
1.60B	1.40B	1.22B	1.36B	1.71B	1.28B
	Net Income Common Stockholders
321.75M	406.40M	310.30M	610.20M	782.60M	539.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.22B	613.90M	1.22B	486.60M	515.30M	912.40M
	Total Assets
10.89B	10.89B	10.89B	10.08B	9.33B	8.58B
	Total Debt
4.93B	3.61B	3.93B	3.33B	2.75B	3.15B
	Net Debt
4.18B	3.00B	2.71B	2.84B	2.24B	2.24B
	Total Liabilities
6.75B	5.50B	5.75B	5.23B	4.66B	4.86B
	Stockholders Equity
4.08B	5.34B	5.08B	4.78B	4.65B	3.69B
Cash Flow		Free Cash Flow
870.15M	790.50M	467.80M	476.10M	990.30M	868.00M
	Operating Cash Flow
1.50B	1.32B	1.02B	1.14B	1.51B	1.22B
	Investing Cash Flow
-1.02B	-846.50M	-681.10M	-855.90M	-1.03B	-525.00M
	Financing Cash Flow
-211.55M	-1.09B	495.80M	-311.30M	-910.30M	-48.60M

Eurofins Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 59.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 59.62 is above the 20-day moving average (MA) of 57.03, above the 50-day MA of 53.72, and above the 200-day MA of 50.44, indicating a bullish trend. The MACD of 1.17 indicates Positive momentum. The RSI at 65.56 is Neutral, neither overbought nor oversold. The STOCH value of 82.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.

Eurofins Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERF	74 Outperform	€10.86B	27.96	9.66%	1.01%	6.70%	32.29%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
0RUG		€14.42B	33.21	10.86%	0.70%	―	―
0MH6		€8.55B	24.72	8.89%	1.16%	―	―
0RG8		€19.35B	94.48	5.24%	0.35%	―	―
E8TN		€253.14M	62.92	2.27%	―	―	―
ZEP2			―		―	―	―